Overexpression of phosphatidylinositol 4-kinase type IIIα is associated with undifferentiated status and poor prognosis of human hepatocellular carcinoma
- Adeodat Ilboudo†1, 3, 4,
- Jean-Charles Nault†5, 6,
- Hélène Dubois-Pot-Schneider2, 3, 4,
- Anne Corlu2, 3, 4,
- Jessica Zucman-Rossi5, 6,
- Michel Samson1, 3, 4 and
- Jacques Le Seyec1, 3, 4Email author
© Ilboudo et al.; licensee BioMed Central Ltd. 2014
Received: 11 June 2013
Accepted: 26 November 2013
Published: 6 January 2014
Hepatocellular carcinoma (HCC) is a particularly severe disease characterized by a high rate of recurrence and death even after surgical resection. Molecular characterization of HCC helps refine prognosis and may facilitate the development of improved therapy. Phosphatidylinositol 4-kinases have recently been identified as cellular factors associated with cancer. Also, phosphatidylinositol 4-kinase type IIIα (PI4KA) is necessary for the propagation of the hepatitis C virus, a major etiological factor for HCC.
Reverse transcription, quantitative real-time PCR was used to assay PI4KA mRNA. The expression levels were investigated both in a collection of molecularly and clinically characterized hepatic tissues from 344 patients with diverse liver diseases and in human hepatocyte cell lines whose proliferative and differentiation status was controlled by specific culture conditions. Analytical microarray data for 60 HCC and six normal liver tissue samples were exploited to study correlations between PI4KA mRNA levels and cell proliferation markers in vivo. Postoperative disease-specific survival and time to recurrence in a set of 214 patients with HCC were studied by univariate and multivariate analyses.
PI4KA mRNA was more abundant in HCC than normal healthy tissues. This upregulation correlated significantly with both poor differentiation and the active proliferation rate in HCC. These associations were confirmed with in vitro models. Moreover, patients with HCC who had been treated by surgical resection and had higher PI4KA mRNA concentrations in their tumor tissue exhibited a higher risk of tumor recurrence (median time: 20 months versus 49 months, P = 0.0012) and shorter disease-specific survival (first quartile time: 16 months versus 48 months, P = 0.0004). Finally, the abundance of PI4KA mRNA proved to be an independent prognostic marker of survival for cases of HCC (hazard ratio = 2.36, P = 0.0064).
PI4KA mRNA could be used as a new molecular marker to improve established prognostic models for HCC. These findings also indicate possible new lines of research for the development of innovative therapeutic approaches targeting PI4KA.
KeywordsHepatocellular carcinoma PI4KA Biomarker Prognosis
Liver cancers are the third leading cause of death by cancer worldwide, and are the sixth most common group of malignancies . Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver (70-80%), more frequent than cholangiocarcinoma, and is more frequent in men than in women . It rarely occurs in normal liver. In western countries, HCC mostly affects patients already suffering from cirrhosis due to chronic alcohol intake, or to chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections . Some cases of HCC emerge by malignant transformation of hepatocellular adenomas (HCA). HCA are benign hepatocellular tumors that develop mostly in otherwise normal liver in women taking oral contraception . Classifications for HCA and HCC, based on their molecular signatures, have been established to refine prognosis and to facilitate work to develop targeted therapies. Thus, a genotype/phenotype classification identified five different molecular subgroups of HCA: (i) hepatocyte nuclear factor 1 homeobox A (HNF1A) mutated, (ii) inflammatory, (iii) catenin (cadherin-associated protein) beta 1 (CTNNB1) mutated, (iv) inflammatory and CTNNB1 mutated, and (v) unclassified. The presence of mutations in the CTNNB1 gene is a factor for poor prognosis, as they are associated with a high risk of malignant transformation of HCA to HCC [5, 6]. Several transcriptomic classifications of HCC provide evidence of the substantial genetic and phenotypic heterogeneity of this tumor type . One of these classifications individualizes six molecular subgroups (G1 to G6) related to clinical and pathological features . However, the mechanisms underlying the molecular and phenotypic differences between HCCs remain to be deciphered.
There has been growing interest in phosphatidylinositol 4-kinase type IIIα (PI4KA) and its involvement in liver disease. We and others have shown that this enzyme is required for the propagation of HCV, one of the main etiological factors of HCC [9–13]. Four different phosphatidylinositol 4-kinases (PI4Ks) are expressed in human cells . These isoenzymes (PI4KA, PI4KB, PI4K2A and PI4K2B) catalyze the phosphorylation of phosphatidylinositol (PtdIns) in the cytoplasmic face of cellular membranes, leading to the production of phosphatidylinositol 4-phosphate (PtdIns4P). Each isozyme displays a specific subcellular distribution. Thus, PI4KA is mainly found in the endoplasmic reticulum (ER). Its activity seems to regulate both the formation of ER exit sites [15, 16] and the concentration of PtdIns4P in the plasma membrane . PtdIns4P is a precursor of other phosphoinositides (PIs), generated by additional phosphorylation(s), involved in a wide range of cellular functions . For example, cell migration and proliferation are controlled by PI-dependent signaling pathways involving phospholipase C (PLC) isozymes or phosphoinositide 3-kinases. Therefore, it is unsurprising that some cancers are associated with various types of deregulation in these signaling pathways, including those affecting PI4Ks .
The analysis of PI4KA expression in various liver diseases may therefore be informative. It may improve the molecular characterization of HCC, providing diagnostic and prognostic tools, and may even be useful to adapt and improve therapy. Moreover, the importance of PI4KA to the HCV life cycle makes it a potential therapeutic target. However, any treatment targeting PI4KA may be affected by its expression. In this context, we investigated PI4KA expression in large cohort of liver diseases. Because antibodies suitable for the detection of the endogenous protein by immunohistochemistry are not available, we used quantitative RT-PCR to assay PI4KA mRNA. We found that the PI4KA gene was more strongly expressed in HCC than in normal liver. This expression was correlated with the differentiation status. PI4KA also appeared to be an independent marker of an unfavorable prognosis in HCC.
All patients gave written consent as required by French law. This study was approved by our local IRB committees (CCPRB for “Comité Consultatif de Protection des Personnes dans la Recherche Biomédicale” Paris Saint Louis and CPP for “Comité de Protection des Personnes” Ouest V). Liver tissues were collected in French hospitals and immediately frozen in liquid nitrogen after surgical resection. The first library included a total of 344 liver samples with five normal and 339 pathological tissues (21 cirrhosis, 101 HCA and 217 HCC). Two additional normal tissue samples were used as calibrators for the relative levels of transcripts in samples as determined by quantitative RT-PCR. The molecular subtype of each of the 101 HCA (see Additional file 1 for clinical and molecular features) was determined according to an established molecular classification using gene mutation and immunohistochemistry staining [4–6]. The set of 217 HCC included in this study has already been extensively described (the main clinical, pathological and molecular features are presented in Additional file 2) . All HCC were screened for TP53 and CTNNB1 mutations and were classified using the G1-G6 molecular classification as previously described [8, 21]. The second cohort consisted of liver fragments from 31 patients who underwent surgical resection for hepatic metastases; these fragments were taken in macroscopically normal liver at a distance from the metastasis.
Huh-7.5.1 and HepaRG cell cultures were maintained as previously described and were subjected to specific differentiation protocols [22, 23]. Huh-7.5.1 cells were seeded at a density of 6 × 104 per cm2 in standard medium, consisting of complete DMEM (Life Technologies) supplemented with 100 U/ml penicillin (Life Technologies), 100 μg/ml streptomycin (Life Technologies), 2 mM L-glutamine (Life Technologies), 10 mM HEPES (Life Technologies), nonessential amino acids (Sigma-Aldrich) and 10% heat-inactivated fetal bovine serum (Hyclone, Logan, UT, USA). When the culture reached 95% confluence, defined as day 0 (D0), the standard culture medium was supplemented with 1% dimethyl sulfoxide (DMSO, Sigma-Aldrich) for 6 consecutive days. Cells were collected on days 0, 1, 3 and 6 (D0, D1, D3 and D6, respectively). HepaRG cells were seeded at a density of 2.7 x 104 per cm2 on day 0 and maintained for two weeks in William’s E medium (Life Technologies) supplemented with 100 U/ml penicillin (Life Technologies), 100 μg/ml streptomycin (Life Technologies), 5 μg/ml insulin (Sigma-Aldrich), 50 μM hydrocortisone hemisuccinate (Roussel) and 10% fetal bovine serum (Hyclone, Logan, UT, USA). Then, the culture medium was or was not supplemented with 2% DMSO (Sigma-Aldrich) for two additional weeks. Cells were collected at days 4, 15 and 30 post-seeding (D4, D15 and D30, respectively). D30- and D30+ indicate that cells were cultured without DMSO for 30 days or without DMSO for 15 days and then with 2% DMSO for 15 days, respectively.
Quantitative RT-PCR and microarray analysis
DNA and RNA were purified with commercial kits (Qiagen). Quantitative RT-PCR and its data analysis were performed as previously described . TaqMan gene expression assays (hs99999901_s1 and hs01021084m1, Applied Biosystems) were used to analyze 18S and PI4KA expression, respectively. The last assay detected both PI4KA mRNA variants referenced in GenBank (NM_058004.3 = Variant 1, NM_002650.2 = Variant 2) with no amplification of pseudogene products. The probe hybridizes at the exon-exon junctions 39–40 and 7–8 of variants 1 and 2, respectively. For absolute quantification, a plasmid (pCMV-SPORT6-hPI4KA, Open Biosystems) containing the PI4KA cDNA (BC018120) was used for calibration. The sequences of the other primers used are given in Additional file 3. The microarray data (60 HCC and 6 normal livers) have been extensively described previously  and are available on a public database (E-TABM-36).
Continuous data were compared using the non-parametric Mann–Whitney Test (two groups) or Kruskal-Wallis Test (more than two groups). Spearman or Pearson tests were used for correlation analysis according to sample size. We used the Mantel Cox log rank test and Kaplan Meier method to assess post-resection survival. Disease-specific survival is defined by the tumor-related death and patients who died of another etiology were censored. Recurrence-free survival was defined as the length of time after hepatectomy for HCC during which a patient survives with no sign of HCC. The last recorded follow-up visit was in February 2011. Univariate analysis using Cox models was performed to identify variables associated with disease-specific survival. Variables with a P value < 0.05 in the univariate analysis were entered into a Cox multivariate model. P values < 0.05 were considered as significant. Statistical analysis was performed using Graphpad Prism and R statistical software (http://www.R-project.org/).
This study adheres to the REMARK guidelines .
Results and discussion
PI4KA transcript levels in pathological human livers
The level of PI4KA transcripts was 2.1 times higher (Mann–Whitney test: P = 0.0023) in HCC than normal reference samples (Figure 1A). The PI4KA mRNA values, however, did not differ significantly between HCC from patients with and without chronic HCV infection (data not shown). This is consistent with the observation that HCV promotes its replication by stimulating the activity of PI4KA but not the expression of its gene .
Influence of differentiation/proliferative status of cancerous liver cells on PI4KA transcript levels
The overexpression of PI4KA in HCC could not be explained by HNF1A mutations: the frequency of these mutations was low in our HCC series (<4%) . By contrast, the mutation of this hepatic differentiation factor was associated with upregulation of PI4KA mRNA in HCA. We therefore looked for an association between the differentiation state of HCC and amounts of the PI4KA transcript. We found that the less differentiated HCC, according to the Edmonson classification, showed stronger PI4KA expression (compare grades I-II with grades III-IV in Figure 1C).
While PI4K2A has been shown to be up-regulated in at least seven types of human cancer , our work reports for the first time a rise of PI4KA transcript levels in a human carcinoma. The reason of this up-regulation in HCC remains to be determined. However, studies suggest that PI4KA may regulate signaling pathways involved in survival and proliferation .
Prognostic significance of PI4KA transcript upregulation
Univariate and multivariate analysis of clinical, pathological and molecular variables for disease-specific survival in 214 HCC
HCC > 5 cm
AFP > 20 ng/ml
Tumor portal thrombosis
Differentiation: Edmonson III/IV
PI4KA high level
Our study clearly shows that PI4KA transcripts are more abundant in HCC than normal liver tissue, and that this upregulation is correlated to their differentiation/proliferation status and is associated with poor survival. Further work is needed to determine the involvement, if any, of PI4KA in HCC pathogenesis.
Hepatitis B virus
Hepatitis C virus
Hepatocyte nuclear factor 1 homeobox A
Catenin (cadherin-associated protein) beta 1
Tumor protein p53
Phosphatidylinositol 4-kinase type IIIα
Polymerase chain reaction
Proliferating cell nuclear antigen
Antigen identified by monoclonal antibody Ki-67.
We thank Dr. Francis Chisari (Scripps Research Institute, La Jolla, CA, USA) for the Huh-7.5.1 cells and the Biological Resource Centre of Rennes for providing the normal human liver specimens. This work was supported by the Institute National de la Santé et de la Recherche Médicale (INSERM), the University of Rennes 1, the Comité Grand-Ouest de la Ligue contre le Cancer, the Ligue Nationale contre le Cancer (“Cartes d’identité des tumeurs” program), IntegraGen (OSEO), HEPTROMIC (FP7), the PAIR-CHC project NoFLIC (funded by INCa and Association pour la Recherche contre le Cancer, ARC), the Réseau national CRB Foie, INCa (WntHCC) and BioIntelligence (OSEO). AI is supported by a fellowship from the Ministère de l′Education and from the ARC. JCN is supported by a grant from the INCa. HDPS is supported by grants from LIV-ES and the Contrat de Plan Etat Région (axe biothérapie).
- Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010, 127 (12): 2893-2917. 10.1002/ijc.25516.View ArticlePubMedGoogle Scholar
- El-Serag HB: Hepatocellular carcinoma. The New England journal of medicine. 2011, 365 (12): 1118-1127. 10.1056/NEJMra1001683.View ArticlePubMedGoogle Scholar
- Forner A, Llovet JM, Bruix J: Hepatocellular carcinoma. Lancet. 2012, 379 (9822): 1245-1255. 10.1016/S0140-6736(11)61347-0.View ArticlePubMedGoogle Scholar
- Nault JC, Bioulac-Sage P, Zucman-Rossi J: Hepatocellular Benign Tumors-From Molecular Classification to Personalized Clinical Care. Gastroenterology. 2013, 144 (5): 888-902. 10.1053/j.gastro.2013.02.032.View ArticlePubMedGoogle Scholar
- Bioulac-Sage P, Rebouissou S, Thomas C, Blanc JF, Saric J, Sa Cunha A, Rullier A, Cubel G, Couchy G, Imbeaud S, et al: Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology. 2007, 46 (3): 740-748. 10.1002/hep.21743.View ArticlePubMedGoogle Scholar
- Zucman-Rossi J, Jeannot E, Nhieu JT, Scoazec JY, Guettier C, Rebouissou S, Bacq Y, Leteurtre E, Paradis V, Michalak S, et al: Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology. 2006, 43 (3): 515-524. 10.1002/hep.21068.View ArticlePubMedGoogle Scholar
- Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM: Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis. 2010, 30 (1): 35-51. 10.1055/s-0030-1247131.View ArticlePubMedPubMed CentralGoogle Scholar
- Boyault S, Rickman DS, De Reynies A, Balabaud C, Rebouissou S, Jeannot E, Herault A, Saric J, Belghiti J, Franco D, et al: Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology. 2007, 45 (1): 42-52. 10.1002/hep.21467.View ArticlePubMedGoogle Scholar
- Berger KL, Cooper JD, Heaton NS, Yoon R, Oakland TE, Jordan TX, Mateu G, Grakoui A, Randall G: Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication. Proc Natl Acad Sci U S A. 2009, 106 (18): 7577-7582. 10.1073/pnas.0902693106.View ArticlePubMedPubMed CentralGoogle Scholar
- Borawski J, Troke P, Puyang X, Gibaja V, Zhao S, Mickanin C, Leighton-Davies J, Wilson CJ, Myer V, Cornellataracido I, et al: Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication. J Virol. 2009, 83 (19): 10058-10074. 10.1128/JVI.02418-08.View ArticlePubMedPubMed CentralGoogle Scholar
- Tai AW, Benita Y, Peng LF, Kim SS, Sakamoto N, Xavier RJ, Chung RT: A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microbe. 2009, 5 (3): 298-307. 10.1016/j.chom.2009.02.001.View ArticlePubMedPubMed CentralGoogle Scholar
- Trotard M, Lepere-Douard C, Regeard M, Piquet-Pellorce C, Lavillette D, Cosset FL, Gripon P, Le Seyec J: Kinases required in hepatitis C virus entry and replication highlighted by small interference RNA screening. Faseb J. 2009, 23 (11): 3780-3789. 10.1096/fj.09-131920.View ArticlePubMedGoogle Scholar
- Vaillancourt FH, Pilote L, Cartier M, Lippens J, Liuzzi M, Bethell RC, Cordingley MG, Kukolj G: Identification of a lipid kinase as a host factor involved in hepatitis C virus RNA replication. Virology. 2009, 387 (1): 5-10. 10.1016/j.virol.2009.02.039.View ArticlePubMedGoogle Scholar
- Minogue S, Waugh MG: The Phosphatidylinositol 4-Kinases: Don’t Call it a Comeback. Subcell Biochem. 2012, 58: 1-24. 10.1007/978-94-007-3012-0_1.View ArticlePubMedGoogle Scholar
- Blumental-Perry A, Haney CJ, Weixel KM, Watkins SC, Weisz OA, Aridor M: Phosphatidylinositol 4-phosphate formation at ER exit sites regulates ER export. Dev Cell. 2006, 11 (5): 671-682. 10.1016/j.devcel.2006.09.001.View ArticlePubMedGoogle Scholar
- Farhan H, Weiss M, Tani K, Kaufman RJ, Hauri HP: Adaptation of endoplasmic reticulum exit sites to acute and chronic increases in cargo load. Embo J. 2008, 27 (15): 2043-2054. 10.1038/emboj.2008.136.View ArticlePubMedPubMed CentralGoogle Scholar
- Balla A, Kim YJ, Varnai P, Szentpetery Z, Knight Z, Shokat KM, Balla T: Maintenance of hormone-sensitive phosphoinositide pools in the plasma membrane requires phosphatidylinositol 4-kinase IIIalpha. Mol Biol Cell. 2008, 19 (2): 711-721.View ArticlePubMedPubMed CentralGoogle Scholar
- Di Paolo G, De Camilli P: Phosphoinositides in cell regulation and membrane dynamics. Nature. 2006, 443 (7112): 651-657. 10.1038/nature05185.View ArticlePubMedGoogle Scholar
- Waugh MG: Phosphatidylinositol 4-kinases, phosphatidylinositol 4-phosphate and cancer. Cancer Lett. 2012, 325 (2): 125-131. 10.1016/j.canlet.2012.06.009.View ArticlePubMedGoogle Scholar
- Nault JC, De Reynies A, Villanueva A, Calderaro J, Rebouissou S, Couchy G, Decaens T, Franco D, Imbeaud S, Rousseau F, et al: A Hepatocellular Carcinoma 5-Gene Score Associated with Survival of Patients Following Liver Resection. Gastroenterology. 2013, 145 (1): 176-187. 10.1053/j.gastro.2013.03.051.View ArticlePubMedGoogle Scholar
- Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, Binot F, Monges G, Thomas G, Bioulac-Sage P, Zucman-Rossi J: Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology. 2001, 120 (7): 1763-1773. 10.1053/gast.2001.24798.View ArticlePubMedGoogle Scholar
- Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, Guyomard C, Lucas J, Trepo C, Guguen-Guillouzo C: Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A. 2002, 99 (24): 15655-15660. 10.1073/pnas.232137699.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T, Chisari FV: Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A. 2005, 102 (26): 9294-9299. 10.1073/pnas.0503596102.View ArticlePubMedPubMed CentralGoogle Scholar
- Rebouissou S, Imbeaud S, Balabaud C, Boulanger V, Bertrand-Michel J, Terce F, Auffray C, Bioulac-Sage P, Zucman-Rossi J: HNF1alpha inactivation promotes lipogenesis in human hepatocellular adenoma independently of SREBP-1 and carbohydrate-response element-binding protein (ChREBP) activation. J Biol Chem. 2007, 282 (19): 14437-14446. 10.1074/jbc.M610725200.View ArticlePubMedGoogle Scholar
- McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: Reporting recommendations for tumor marker prognostic studies. J Clin Oncol. 2005, 23 (36): 9067-9072. 10.1200/JCO.2004.01.0454.View ArticlePubMedGoogle Scholar
- Odom DT, Zizlsperger N, Gordon DB, Bell GW, Rinaldi NJ, Murray HL, Volkert TL, Schreiber J, Rolfe PA, Gifford DK, et al: Control of pancreas and liver gene expression by HNF transcription factors. Science. 2004, 303 (5662): 1378-1381. 10.1126/science.1089769.View ArticlePubMedPubMed CentralGoogle Scholar
- Reiss S, Rebhan I, Backes P, Romero-Brey I, Erfle H, Matula P, Kaderali L, Poenisch M, Blankenburg H, Hiet MS, et al: Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe. 2011, 9 (1): 32-45. 10.1016/j.chom.2010.12.002.View ArticlePubMedPubMed CentralGoogle Scholar
- Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, Calderaro J, Bioulac-Sage P, Letexier M, Degos F, et al: Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet. 2012, 44 (6): 694-698. 10.1038/ng.2256.View ArticlePubMedPubMed CentralGoogle Scholar
- Sainz B, Chisari FV: Production of infectious hepatitis C virus by well-differentiated, growth-arrested human hepatoma-derived cells. J Virol. 2006, 80 (20): 10253-10257. 10.1128/JVI.01059-06.View ArticlePubMedPubMed CentralGoogle Scholar
- Parent R, Marion MJ, Furio L, Trepo C, Petit MA: Origin and characterization of a human bipotent liver progenitor cell line. Gastroenterology. 2004, 126 (4): 1147-1156. 10.1053/j.gastro.2004.01.002.View ArticlePubMedGoogle Scholar
- Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, Durnez A, Demetris AJ, Thorgeirsson SS: Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology. 2004, 40 (3): 667-676. 10.1002/hep.20375.View ArticlePubMedGoogle Scholar
- Li J, Lu Y, Zhang J, Kang H, Qin Z, Chen C: PI4KIIalpha is a novel regulator of tumor growth by its action on angiogenesis and HIF-1alpha regulation. Oncogene. 2010, 29 (17): 2550-2559. 10.1038/onc.2010.14.View ArticlePubMedGoogle Scholar
- Ishikawa S, Egami H, Kurizaki T, Akagi J, Tamori Y, Yoshida N, Tan X, Hayashi N, Ogawa M: Identification of genes related to invasion and metastasis in pancreatic cancer by cDNA representational difference analysis. J Exp Clin Cancer Res. 2003, 22 (2): 299-306.PubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/14/7/prepub
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.